Cyclic AMP Signaling in Biliary Proliferation: a Possible Target for Cholangiocarcinoma Treatment?

Total Page:16

File Type:pdf, Size:1020Kb

Cyclic AMP Signaling in Biliary Proliferation: a Possible Target for Cholangiocarcinoma Treatment? cells Review Cyclic AMP Signaling in Biliary Proliferation: A Possible Target for Cholangiocarcinoma Treatment? Leonardo Baiocchi 1, Ilaria Lenci 1, Martina Milana 1, Lindsey Kennedy 2,3, Keisaku Sato 2 , Wenjun Zhang 4, Burcin Ekser 4 , Ludovica Ceci 2, Vik Meadows 2, Shannon Glaser 5, Gianfranco Alpini 2,3,*,† and Heather Francis 2,3,*,† 1 Hepatology Unit, University of Tor Vergata, 00133 Rome, Italy; [email protected] (L.B.); [email protected] (I.L.); [email protected] (M.M.) 2 Hepatology and Gastroenterology, Medicine, Indiana University, Indianapolis, IN 46202, USA; [email protected] (L.K.); [email protected] (K.S.); [email protected] (L.C.); [email protected] (V.M.) 3 Richard L. Roudebush VA Medical Center, Indianapolis, IN 46202, USA 4 Division of Transplant Surgery, Department of Surgery, Indiana University, Indianapolis, IN 46202, USA; [email protected] (W.Z.); [email protected] (B.E.) 5 Department of Medical Physiology, Texas A&M University College of Medicine, Bryan, TX 77807, USA; [email protected] * Correspondence: [email protected] (G.A.); [email protected] (H.F.) † These authors contributed equally to this work. Abstract: Cholangiocarcinoma is a lethal disease with scarce response to current systemic therapy. The rare occurrence and large heterogeneity of this cancer, together with poor knowledge of its molecular mechanisms, are elements contributing to the difficulties in finding an appropriate cure. Cholangiocytes (and their cellular precursors) are considered the liver component giving rise to Citation: Baiocchi, L.; Lenci, I.; cholangiocarcinoma. These cells respond to several hormones, neuropeptides and molecular stimuli Milana, M.; Kennedy, L.; Sato, K.; employing the cAMP/PKA system for the translation of messages in the intracellular space. For Zhang, W.; Ekser, B.; Ceci, L.; Meadows, V.; Glaser, S.; et al. Cyclic instance, in physiological conditions, stimulation of the secretin receptor determines an increase AMP Signaling in Biliary of intracellular levels of cAMP, thus activating a series of molecular events, finally determining in Proliferation: A Possible Target for bicarbonate-enriched choleresis. However, activation of the same receptor during cholangiocytes’ Cholangiocarcinoma Treatment? Cells injury promotes cellular growth again, using cAMP as the second messenger. Since several scientific 2021, 10, 1692. https://doi.org/ pieces of evidence link cAMP signaling system to cholangiocytes’ proliferation, the possible changes 10.3390/cells10071692 of this pathway during cancer growth also seem relevant. In this review, we summarize the current findings regarding the cAMP pathway and its role in biliary normal and neoplastic cell proliferation. Academic Editor: Isabel Fabregat Perspectives for targeting the cAMP machinery in cholangiocarcinoma therapy are also discussed. Received: 25 May 2021 Keywords: cholangiocarcinoma; cAMP; cholangiocytes; proliferation; PKA; secretin Accepted: 30 June 2021 Published: 4 July 2021 Publisher’s Note: MDPI stays neutral 1. Introduction with regard to jurisdictional claims in published maps and institutional affil- The biliary tree is lined by epithelial cells (i.e., cholangiocytes), which appear to iations. originate from a common stem cell compartment, the hepatic progenitor cells, similar to hepatocytes [1]. These pluripotent cells are located at the interface between the hepatocyte canaliculi and bile ductules in the canals of Hering (Figure1), the latter being the smaller branches of the biliary tree [2]. The canals of Hering extend to the interlobular ducts (i.e., bile ductules, 15–100 µm Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland. in diameter), then continue in the septal area, segmental and finally, in the right and left This article is an open access article hepatic ducts, joining together at the hepatic hilum. This portion of the biliary epithe- distributed under the terms and lium is regarded as the intrahepatic one, whereas the part extending outside the liver and conditions of the Creative Commons comprising the common bile duct, the gallbladder (with cystic duct) and choledochus is Attribution (CC BY) license (https:// defined as extrahepatic [1]. Via electron microscopy, two different cholangiocyte subpopu- creativecommons.org/licenses/by/ lations in rodent livers are well recognized (small and large), lining small ducts (≤15 µm in 4.0/). diameter) or large ducts (≥15 µm in diameter) according to their size [1,3]. Large cyclic Cells 2021, 10, 1692. https://doi.org/10.3390/cells10071692 https://www.mdpi.com/journal/cells Cells 2021, 10, 1692 2 of 14 adenosine monophosphate (cAMP)-dependent cholangiocytes are considered the func- tional part of the biliary tree since they respond to gastrointestinal hormones (e.g., secretin), neuro-peptides and other modulators [4–6]. On the other hand, small Ca2+-dependent cholangiocytes [7] do not respond to secretin and proliferate to replenish the biliary epithe- lium (during damage to the large, cAMP-dependent cholangiocytes) by amplification of Ca2+-dependent signaling and de novo acquisition of large cholangiocyte phenotypes [6,8,9]. While, at the beginning, just bile duct secretory activities were studied with regard to biliary tract diseases, lately also, biliary proliferative phenotypes have gained interest [10–12]. Cells 2021, 10, x For instance, atypical cholangiocyte proliferation, characterized by truncated tortuous2 of bile 15 ducts, has been observed in adult cholestatic liver diseases such as primary biliary cholan- gitis (PBC) and primary sclerosing cholangitis (PSC) [13,14]. Both diseases are defined as ductopenia, since changes and evolution of proliferation determine a reduction of total bile ducts in the end [15]. BILE Bile canaliculi Canals of Hering Bile ductules Bile duct Hepatocytes Stem cells Cholangiocytes Cholangiocytes Figure 1. The main cells and ultrastructural districts encountered by the bile (black arrow) while moving from the hepatocytes to the bile ducts. FigureIn 1. cholangiocarcinoma The main cells and ultrastructu (CCA), cellularral districts growth encountered and expansion by the bile also (black deserve arrow) interest while as possiblemoving from targets the hepatocy for therapy.tes to Several the bile ducts. molecular cascades such as the Janus kinase/signal transducer and activator of transcription, p38 MAP kinase (MAPK), Akt (AKA, protein kinaseThe B, canals PKB) orof fibroblastHering extend growth to factor/fibroblastthe interlobular ducts growth (i.e., factor bile receptorductules, may15–100 stimu- μm latein diameter), cell growth then and continue impact biliaryin the septal proliferation area, segmental [16,17]. Both and hyperplastic finally, in the and right neoplastic and left cholangiocytehepatic ducts, joining growth together are frequently at the hepatic associated hilum. with This changes portion in of intracellular the biliary epithelium cAMP lev- elsis regarded [18]. In as this the review, intrahepatic after one, a general wherea descriptions the part extending of cAMP outside signaling the and liver its and role com- in parenchymalprising the common and biliary bile cell duct, functions, the gallbladder we will discuss(with cystic the most duct) recent and findingscholedochus regarding is de- thefined relationship as extrahepatic between [1]. the Via cAMP-dependent electron microscopy, pathway two anddifferent cancer cholangiocyte of the biliary tractsubpopu- (e.g., cholangiocarcinoma).lations in rodent livers are well recognized (small and large), lining small ducts (≤15 μm in diameter) or large ducts (≥15 μm in diameter) according to their size [1,3]. Large cyclic 2.adenosine cAMP Signaling monophosphate (cAMP)-dependent cholangiocytes are considered the func- tionalcAMP part of was the first biliary discovered tree since in 1958they re andspond introduced to gastrointestinal the concept hormones of a “second (e.g., messen- secre- ger”tin), neuro-peptides system [19]. In and fact, other this molecule, modulators together [4–6]. On with the cyclic other guanosinehand, small monophosphate Ca2+-dependent (cGMP),cholangiocytes has been [7] identifieddo not respond as an important to secretin intracellular and proliferate translator to replenish of membrane the biliary signal- epi- ingthelium originating (during from damage hormones, to the large, growth cAMP-d factors,ependent cytokines cholangiocytes) and other molecules by amplification [20]. In theof Ca general2+-dependent transduction signaling mechanism, and de novo the stimulated acquisition receptor of large activates cholangiocyte the corresponding phenotypes G-coupled[6,8,9]. While, protein, at the leading beginning, to increased just bile duct adenylyl secretory cyclase-mediated activities were cAMP studied synthesis. with regard The followingto biliary tract steps diseases, include cAMPlately bindingalso, biliary to protein proliferative kinase phenotypes A (PKA) or anhave exchange gained proteininterest activated[10–12]. For by instance, cAMP (EPAC) atypical and cholangiocyte also cyclic nucleotide-gated proliferation, characterized ion channels by [21 truncated]. Canonical tor- G-protein-coupledtuous bile ducts, has receptor/cAMP/PKA been observed in adul signalingt cholestatic is depicted liver indiseases Figure2 such. as primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC) [13,14]. Both diseases are defined as ductopenia, since changes and evolution of proliferation determine a re- duction of total bile ducts in the end [15]. In cholangiocarcinoma (CCA), cellular growth
Recommended publications
  • Secretin and Autism: a Clue but Not a Cure
    SCIENCE & MEDICINE Secretin and Autism: A Clue But Not a Cure by Clarence E. Schutt, Ph.D. he world of autism has been shaken by NBC’s broadcast connections could not be found. on Dateline of a film segment documenting the effect of Tsecretin on restoring speech and sociability to autistic chil- The answer was provided nearly one hundred years ago by dren. At first blush, it seems unlikely that an intestinal hormone Bayless and Starling, who discovered that it is not nerve signals, regulating bicarbonate levels in the stomach in response to a but rather a novel substance that stimulates secretion from the good meal might influence the language centers of the brain so cells forming the intestinal mucosa. They called this substance profoundly. However, recent discoveries in neurobiology sug- “secretin.” They suggested that there could be many such cir- gest several ways of thinking about the secretin-autism connec- culating substances, or molecules, and they named them “hor- tion that could lead to the breakthroughs we dream about. mones” based on the Greek verb meaning “to excite”. As a parent with more than a decade of experience in consider- A simple analogy might help. If the body is regarded as a commu- ing a steady stream of claims of successful treatments, and as a nity of mutual service providers—the heart and muscles are the pri- scientist who believes that autism is a neurobiological disorder, I mary engines of movement, the stomach breaks down foods for have learned to temper my hopes about specific treatments by distribution, the liver detoxifies, and so on—then the need for a sys- seeing if I could construct plausible neurobiological mechanisms tem of messages conveyed by the blood becomes clear.
    [Show full text]
  • Constitutive Activation of G Protein-Coupled Receptors and Diseases: Insights Into Mechanisms of Activation and Therapeutics
    Pharmacology & Therapeutics 120 (2008) 129–148 Contents lists available at ScienceDirect Pharmacology & Therapeutics journal homepage: www.elsevier.com/locate/pharmthera Associate editor: S. Enna Constitutive activation of G protein-coupled receptors and diseases: Insights into mechanisms of activation and therapeutics Ya-Xiong Tao ⁎ Department of Anatomy, Physiology and Pharmacology, 212 Greene Hall, College of Veterinary Medicine, Auburn University, Auburn, AL 36849, USA article info abstract The existence of constitutive activity for G protein-coupled receptors (GPCRs) was first described in 1980s. In Keywords: 1991, the first naturally occurring constitutively active mutations in GPCRs that cause diseases were reported G protein-coupled receptor Disease in rhodopsin. Since then, numerous constitutively active mutations that cause human diseases were reported Constitutively active mutation in several additional receptors. More recently, loss of constitutive activity was postulated to also cause Inverse agonist diseases. Animal models expressing some of these mutants confirmed the roles of these mutations in the Mechanism of activation pathogenesis of the diseases. Detailed functional studies of these naturally occurring mutations, combined Transgenic model with homology modeling using rhodopsin crystal structure as the template, lead to important insights into the mechanism of activation in the absence of crystal structure of GPCRs in active state. Search for inverse Abbreviations: agonists on these receptors will be critical for correcting the diseases cause by activating mutations in GPCRs. ADRP, autosomal dominant retinitis pigmentosa Theoretically, these inverse agonists are better therapeutics than neutral antagonists in treating genetic AgRP, Agouti-related protein AR, adrenergic receptor diseases caused by constitutively activating mutations in GPCRs. CAM, constitutively active mutant © 2008 Elsevier Inc.
    [Show full text]
  • Individual Protomers of a G Protein-Coupled Receptor Dimer Integrate Distinct Functional Modules
    OPEN Citation: Cell Discovery (2015) 1, 15011; doi:10.1038/celldisc.2015.11 © 2015 SIBS, CAS All rights reserved 2056-5968/15 ARTICLE www.nature.com/celldisc Individual protomers of a G protein-coupled receptor dimer integrate distinct functional modules Nathan D Camp1, Kyung-Soon Lee2, Jennifer L Wacker-Mhyre2, Timothy S Kountz2, Ji-Min Park2, Dorathy-Ann Harris2, Marianne Estrada2, Aaron Stewart2, Alejandro Wolf-Yadlin1, Chris Hague2 1Department of Genome Sciences, University of Washington School of Medicine, Seattle, WA, USA; 2Department of Pharmacology, University of Washington School of Medicine, Seattle, WA, USA Recent advances in proteomic technology reveal G-protein-coupled receptors (GPCRs) are organized as large, macromolecular protein complexes in cell membranes, adding a new layer of intricacy to GPCR signaling. We previously reported the α1D-adrenergic receptor (ADRA1D)—a key regulator of cardiovascular, urinary and CNS function—binds the syntrophin family of PDZ domain proteins (SNTA, SNTB1, and SNTB2) through a C-terminal PDZ ligand inter- action, ensuring receptor plasma membrane localization and G-protein coupling. To assess the uniqueness of this novel GPCR complex, 23 human GPCRs containing Type I PDZ ligands were subjected to TAP/MS proteomic analysis. Syntrophins did not interact with any other GPCRs. Unexpectedly, a second PDZ domain protein, scribble (SCRIB), was detected in ADRA1D complexes. Biochemical, proteomic, and dynamic mass redistribution analyses indicate syntrophins and SCRIB compete for the PDZ ligand, simultaneously exist within an ADRA1D multimer, and impart divergent pharmacological properties to the complex. Our results reveal an unprecedented modular dimeric architecture for the ADRA1D in the cell membrane, providing unexpected opportunities for fine-tuning receptor function through novel protein interactions in vivo, and for intervening in signal transduction with small molecules that can stabilize or disrupt unique GPCR:PDZ protein interfaces.
    [Show full text]
  • Insights Into Nuclear G-Protein-Coupled Receptors As Therapeutic Targets in Non-Communicable Diseases
    pharmaceuticals Review Insights into Nuclear G-Protein-Coupled Receptors as Therapeutic Targets in Non-Communicable Diseases Salomé Gonçalves-Monteiro 1,2, Rita Ribeiro-Oliveira 1,2, Maria Sofia Vieira-Rocha 1,2, Martin Vojtek 1,2 , Joana B. Sousa 1,2,* and Carmen Diniz 1,2,* 1 Laboratory of Pharmacology, Department of Drug Sciences, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal; [email protected] (S.G.-M.); [email protected] (R.R.-O.); [email protected] (M.S.V.-R.); [email protected] (M.V.) 2 LAQV/REQUIMTE, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal * Correspondence: [email protected] (J.B.S.); [email protected] (C.D.) Abstract: G-protein-coupled receptors (GPCRs) comprise a large protein superfamily divided into six classes, rhodopsin-like (A), secretin receptor family (B), metabotropic glutamate (C), fungal mating pheromone receptors (D), cyclic AMP receptors (E) and frizzled (F). Until recently, GPCRs signaling was thought to emanate exclusively from the plasma membrane as a response to extracellular stimuli but several studies have challenged this view demonstrating that GPCRs can be present in intracellular localizations, including in the nuclei. A renewed interest in GPCR receptors’ superfamily emerged and intensive research occurred over recent decades, particularly regarding class A GPCRs, but some class B and C have also been explored. Nuclear GPCRs proved to be functional and capable of triggering identical and/or distinct signaling pathways associated with their counterparts on the cell surface bringing new insights into the relevance of nuclear GPCRs and highlighting the Citation: Gonçalves-Monteiro, S.; nucleus as an autonomous signaling organelle (triggered by GPCRs).
    [Show full text]
  • RT² Profiler PCR Array (96-Well Format and 384-Well [4 X 96] Format)
    RT² Profiler PCR Array (96-Well Format and 384-Well [4 x 96] Format) Human GPCR Signaling PathwayFinder Cat. no. 330231 PAHS-071ZA For pathway expression analysis Format For use with the following real-time cyclers RT² Profiler PCR Array, Applied Biosystems® models 5700, 7000, 7300, 7500, Format A 7700, 7900HT, ViiA™ 7 (96-well block); Bio-Rad® models iCycler®, iQ™5, MyiQ™, MyiQ2; Bio-Rad/MJ Research Chromo4™; Eppendorf® Mastercycler® ep realplex models 2, 2s, 4, 4s; Stratagene® models Mx3005P®, Mx3000P®; Takara TP-800 RT² Profiler PCR Array, Applied Biosystems models 7500 (Fast block), 7900HT (Fast Format C block), StepOnePlus™, ViiA 7 (Fast block) RT² Profiler PCR Array, Bio-Rad CFX96™; Bio-Rad/MJ Research models DNA Format D Engine Opticon®, DNA Engine Opticon 2; Stratagene Mx4000® RT² Profiler PCR Array, Applied Biosystems models 7900HT (384-well block), ViiA 7 Format E (384-well block); Bio-Rad CFX384™ RT² Profiler PCR Array, Roche® LightCycler® 480 (96-well block) Format F RT² Profiler PCR Array, Roche LightCycler 480 (384-well block) Format G RT² Profiler PCR Array, Fluidigm® BioMark™ Format H Sample & Assay Technologies Description The Human G-Protein-Coupled Receptor Signaling PathwayFinder RT² Profiler PCR Array profiles the expression of 84 genes representative of and involved in GPCR-mediated signal transduction pathways. G-protein Coupled Receptors (GPCRs) that are represented on this array include bioactive lipid receptors, metabotropic glutamate receptors (mGluRs), GABA-B-like receptors, rhodopsin-like receptors, and secretin-like receptors. Members of the intricate network of intracellular signaling pathways involved in GPCR-mediated signal transduction are also represented on this array including the cAMP / PKA Pathway, Calcium / PKC Pathway, Calcium / NFAT Pathway, PLC Pathway, Protein Tyrosine Kinase Pathway, PKC / MEK Pathway, p43 / p44MAP Pathway, p38 MAP Pathway, PI-3 Kinase Pathway, NO-cGMP Pathway, Rho Pathway, NFκB Pathway and Jak / Stat Pathway.
    [Show full text]
  • G Protein-Coupled Receptors
    S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2015/16: G protein-coupled receptors. British Journal of Pharmacology (2015) 172, 5744–5869 THE CONCISE GUIDE TO PHARMACOLOGY 2015/16: G protein-coupled receptors Stephen PH Alexander1, Anthony P Davenport2, Eamonn Kelly3, Neil Marrion3, John A Peters4, Helen E Benson5, Elena Faccenda5, Adam J Pawson5, Joanna L Sharman5, Christopher Southan5, Jamie A Davies5 and CGTP Collaborators 1School of Biomedical Sciences, University of Nottingham Medical School, Nottingham, NG7 2UH, UK, 2Clinical Pharmacology Unit, University of Cambridge, Cambridge, CB2 0QQ, UK, 3School of Physiology and Pharmacology, University of Bristol, Bristol, BS8 1TD, UK, 4Neuroscience Division, Medical Education Institute, Ninewells Hospital and Medical School, University of Dundee, Dundee, DD1 9SY, UK, 5Centre for Integrative Physiology, University of Edinburgh, Edinburgh, EH8 9XD, UK Abstract The Concise Guide to PHARMACOLOGY 2015/16 provides concise overviews of the key properties of over 1750 human drug targets with their pharmacology, plus links to an open access knowledgebase of drug targets and their ligands (www.guidetopharmacology.org), which provides more detailed views of target and ligand properties. The full contents can be found at http://onlinelibrary.wiley.com/doi/ 10.1111/bph.13348/full. G protein-coupled receptors are one of the eight major pharmacological targets into which the Guide is divided, with the others being: ligand-gated ion channels, voltage-gated ion channels, other ion channels, nuclear hormone receptors, catalytic receptors, enzymes and transporters. These are presented with nomenclature guidance and summary information on the best available pharmacological tools, alongside key references and suggestions for further reading.
    [Show full text]
  • Multi-Functionality of Proteins Involved in GPCR and G Protein Signaling: Making Sense of Structure–Function Continuum with In
    Cellular and Molecular Life Sciences (2019) 76:4461–4492 https://doi.org/10.1007/s00018-019-03276-1 Cellular andMolecular Life Sciences REVIEW Multi‑functionality of proteins involved in GPCR and G protein signaling: making sense of structure–function continuum with intrinsic disorder‑based proteoforms Alexander V. Fonin1 · April L. Darling2 · Irina M. Kuznetsova1 · Konstantin K. Turoverov1,3 · Vladimir N. Uversky2,4 Received: 5 August 2019 / Revised: 5 August 2019 / Accepted: 12 August 2019 / Published online: 19 August 2019 © Springer Nature Switzerland AG 2019 Abstract GPCR–G protein signaling system recognizes a multitude of extracellular ligands and triggers a variety of intracellular signal- ing cascades in response. In humans, this system includes more than 800 various GPCRs and a large set of heterotrimeric G proteins. Complexity of this system goes far beyond a multitude of pair-wise ligand–GPCR and GPCR–G protein interactions. In fact, one GPCR can recognize more than one extracellular signal and interact with more than one G protein. Furthermore, one ligand can activate more than one GPCR, and multiple GPCRs can couple to the same G protein. This defnes an intricate multifunctionality of this important signaling system. Here, we show that the multifunctionality of GPCR–G protein system represents an illustrative example of the protein structure–function continuum, where structures of the involved proteins represent a complex mosaic of diferently folded regions (foldons, non-foldons, unfoldons, semi-foldons, and inducible foldons). The functionality of resulting highly dynamic conformational ensembles is fne-tuned by various post-translational modifcations and alternative splicing, and such ensembles can undergo dramatic changes at interaction with their specifc partners.
    [Show full text]
  • Initial, Transient, and Specific Interaction Between G Protein
    Sato T. et al. Medical Research Archives, vol. 6, issue 9, September 2018 Page 1 of 25 ARTICLE Initial, transient, and specific interaction between G protein-coupled receptor and target G protein in parallel signal processing: a case of olfactory discrimination of cancer-induced odors Takaaki Sato1, Mutsumi Matsukawa2, Yoichi Mizutani3, Toshio Iijima4, Hiroyoshi Matsumura5 Authors’ affiliations: 1 Biomedical Research Institute, National Institute of Advanced Industrial Science and Technology, Osaka, Japan 2 Division of Anatomical Science, Department of Functional Morphology, Nihon University School of Medicine, Tokyo, Japan 3 Department of Medical Engineering, Faculty of Health Science, Aino University, Osaka, Japan 4 Graduate School of Life Sciences, Tohoku University, Sendai, Japan 5 College of Life Sciences, Ritsumeikan University, Kusatsu, Japan * Corresponding author: Takaaki Sato, Biomedical Research Institute, National Institute of Ad- vanced Industrial Science and Technology, 1-8-31 Midorioka, Ikeda, Osaka 563-8577, Japan, E-mail: [email protected] Abstract: G protein-coupled receptors (GPCRs) detect and distinguish between various subtypes of extracellular sig- nals, such as neurotransmitters, hormones, light, and odorous chemicals. As determinants for robust and appropriate cellular responses, common and unique features of interactions between GPCRs and their target G proteins provide insights into structure-based drug design for treatment of GPCR-related diseases. Re- cently, we found that the hydrophobic core buried between GPCR helix 8 and TM1–2 is essential for acti- vation of both specific and nonspecific G proteins. Furthermore, the 2nd residue of helix 8 is responsible for initial, transient, and specific interaction with a target G protein. Analysis of human and murine olfactory receptors (ORs) and other class-A GPCRs revealed that several amino acids, such as Glu, Gln, and Asp, are conserved at this position.
    [Show full text]
  • Gpcrs Globally Coevolved with Receptor Activity-Modifying Proteins, Ramps
    GPCRs globally coevolved with receptor activity-modifying proteins, RAMPs Shahar Barbasha, Emily Lorenzena, Torbjörn Perssona,b, Thomas Hubera,1, and Thomas P. Sakmara,b,1 aLaboratory of Chemical Biology and Signal Transduction, The Rockefeller University, New York, NY, 10065; and bDepartment of Neurobiology, Care Sciences and Society, Division for Neurogeriatrics, Center for Alzheimer Research, Karolinska Institutet, 141 57 Huddinge, Sweden Edited by Andrew C. Kruse, Harvard University, and accepted by Editorial Board Member K. C. Garcia September 28, 2017 (received for review July 22, 2017) Receptor activity-modifying proteins (RAMPs) are widely expressed between the two. Therefore, highly coevolved protein pairs could in human tissues and, in some cases, have been shown to affect be members in the same pathway, or they could be components surface expression or ligand specificity of G-protein–coupled recep- of the same complex. tors (GPCRs). However, whether RAMP−GPCR interactions are wide- Previously, several cases of coevolution of receptor genes and spread, and the nature of their functional consequences, remains their endogenous protein−ligand genes were reported (13), but largely unknown. In humans, there are three RAMPs and over large-scale coevolution of different signal transduction components 800 expressed GPCRs, making direct experimental approaches chal- was not examined. Phylogenetic analysis to conclude coevolution lenging. We analyzed relevant genomic data from all currently avail- could be implemented by two complementary approaches. The able sequenced organisms. We discovered that RAMPs and GPCRs first searches for ortholog genes across species with the assumption tend to have orthologs in the same species and have correlated that interacting proteins would tend to coexist in genomes (10).
    [Show full text]
  • Unveiling Role of Sphingosine-1-Phosphate Receptor 2 As a Brake of Epithelial Stem Cell Proliferation and a Tumor Suppressor In
    Petti et al. Journal of Experimental & Clinical Cancer Research (2020) 39:253 https://doi.org/10.1186/s13046-020-01740-6 RESEARCH Open Access Unveiling role of sphingosine-1-phosphate receptor 2 as a brake of epithelial stem cell proliferation and a tumor suppressor in colorectal cancer Luciana Petti1, Giulia Rizzo2, Federica Rubbino2, Sudharshan Elangovan2, Piergiuseppe Colombo3, Silvia Restelli1, Andrea Piontini2, Vincenzo Arena4, Michele Carvello5, Barbara Romano6, Tommaso Cavalleri7, Achille Anselmo8, Federica Ungaro2, Silvia D’Alessio2, Antonino Spinelli2,5, Sanja Stifter9, Fabio Grizzi10, Alessandro Sgambato4,11, Silvio Danese1,2, Luigi Laghi7,12, Alberto Malesci2,7 and Stefania Vetrano1,2* Abstract Background: Sphingosine-1-phosphate receptor 2 (S1PR2) mediates pleiotropic functions encompassing cell proliferation, survival, and migration, which become collectively de-regulated in cancer. Information on whether S1PR2 participates in colorectal carcinogenesis/cancer is scanty, and we set out to fill the gap. Methods: We screened expression changes of S1PR2 in human CRC and matched normal mucosa specimens [N = 76]. We compared CRC arising in inflammation-driven and genetically engineered models in wild-type (S1PR2+/+) and S1PR2 deficient (S1PR2−/−) mice. We reconstituted S1PR2 expression in RKO cells and assessed their growth in xenografts. Functionally, we mimicked the ablation of S1PR2 in normal mucosa by treating S1PR2+/+ organoids with JTE013 and characterized intestinal epithelial stem cells isolated from S1PR2−/−Lgr5-EGFP- mice. Results: S1PR2 expression was lost in 33% of CRC; in 55%, it was significantly decreased, only 12% retaining expression comparable to normal mucosa. Both colitis-induced and genetic Apc+/min mouse models of CRC showed a higher incidence in size and number of carcinomas and/or high-grade adenomas, with increased cell proliferation in S1PR2−/− mice compared to S1PR2+/+ controls.
    [Show full text]
  • Cholangiocytes and the Environment in Primary Sclerosing Cholangitis
    Gut Online First, published on July 21, 2017 as 10.1136/gutjnl-2017-314249 Leading article microbial infection (eg, Cryptosporidium Cholangiocytes and the environment in parvum)16 and PSC; (iii) accumulating evidence supporting a critical role for the Gut: first published as 10.1136/gutjnl-2017-314249 on 21 July 2017. Downloaded from primary sclerosing cholangitis: where is intestinal microbiome in the pathogenesis of PSC17; (iv) a similar genetic architecture the link? in PSC as in a prototypical exposure-driven autoimmune disease, coeliac disease18; and 1 2,3 1 (v) a similar genetic architecture in PSC as Steven P O’Hara, Tom H Karlsen, Nicholas F LaRusso 19 20 in cholestatic drug-induced injury. We began studying the cholangiopathy In primary sclerosing cholangitis (PSC), in medicine. Robert Koch in the late 19th in HIV-infected patients (a form of SSC annular fibrosis around intrahepatic and century proposed criteria to identify a due to biliary tract infection by opportu- extrahepatic bile ducts leads to progres- disease as infectious.9 These included nistic pathogens, including C parvum)21 sive liver disease for which there is no (i) the organism is regularly associated both because it was a significant clinical effective therapy except liver transplanta- with the disease, (ii) the organism can problem and as a result of our own clinical tion.1 The concentric accumulation of be isolated from the diseased host and experience with C parvum-induced SSC.22 connective tissue around bile ducts grown in culture and (iii) the disease To summarise key points from multiple suggests that the cholangiocyte plays an can be reproduced when the organism in vitro and in vivo studies,16 23 we found integral role in PSC pathogenesis.
    [Show full text]
  • Expression of Specific Hepatocyte and Cholangiocyte Transcription Factors
    Laboratory Investigation (2008) 88, 865–872 & 2008 USCAP, Inc All rights reserved 0023-6837/08 $30.00 Expression of specific hepatocyte and cholangiocyte transcription factors in human liver disease and embryonic development Pallavi B Limaye, Gabriela Alarco´n, Andrew L Walls, Michael A Nalesnik, George K Michalopoulos, Anthony J Demetris and Erin R Ochoa Transcription factors are major determinants of cell-specific gene expression in all cell types. Studies in rodent liver have shown that alterations in transcription factor expression determine lineage specification during fetal liver development and signify transdifferentiation of cells of the biliary compartment into ‘oval’ cells and eventually hepatocytes in adult liver. We examined the cellular localization of hepatocyte- or BEC-associated transcription factors in human fetal and adult liver and in diseases in which transdifferentiation between hepatocytes and biliary cells may play a role. In the normal adult human liver, hepatocyte nuclear factor (HNF)4a and HNF6 appeared exclusively in hepatocytes; HNF1b, HNF3a, and HNF3b were observed only in BEC. During fetal development both BEC and hepatocytes expressed HNF3a, HNF3b, and HNF6. HNF1a was expressed only in fetal hepatocytes. We further examined expression of transcription factors in massive hepatic necrosis and in specific types of chronic liver disease. Hepatocyte-associated transcription factors HNF4a and HNF6 also appeared in BEC in massive hepatic necrosis and chronic hepatitis C virus infection. Similarly, HNF3b that is expressed only in BEC in normal adult liver was also observed in hepatocytes in primary biliary cirrhosis and chronic biliary obstruction. These data mimic previous findings in rodents in which hepatocyte-associated transcription factors appear in biliary cells prior to emergence of oval cells, which function as progenitor cells for hepatocytes when the regenerative capacity of the latter is compromised.
    [Show full text]